schliessen

Filtern

 

Bibliotheken

Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study

Patients at high risk of cardiovascular disease frequently fail to reach recommended low-density lipoprotein cholesterol (LDL-C) goals, partly because statin doses are not titrated to optimal effect. The ECLIPSE study was designed to compare the efficacy and safety of force-titrated treatment with r... Full description

Journal Title: Cardiology 2008, Vol.111 (4), p.219-28
Main Author: Faergeman, Ole
Other Authors: Hill, Laurie , Windler, Eberhard , Wiklund, Olov , Asmar, Roland , Duffield, Emma , Sosef, Froukje
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: Switzerland: S. Karger AG
ID: ISSN: 0008-6312
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_swepub_primary_oai_gup_ub_gu_se_70461
title: Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study
format: Article
creator:
  • Faergeman, Ole
  • Hill, Laurie
  • Windler, Eberhard
  • Wiklund, Olov
  • Asmar, Roland
  • Duffield, Emma
  • Sosef, Froukje
subjects:
  • Aged
  • Atorvastatin Calcium
  • Canada
  • Cardiovascular disease
  • Cholesterol
  • Cholesterol, LDL - blood
  • CoA Reductase Inhibitors
  • Coronary Disease
  • Coronary Disease - prevention & control
  • Drug dosages
  • Drug therapy
  • European Union
  • Female
  • Fluorobenzenes
  • Fluorobenzenes - administration & dosage
  • Fluorobenzenes - adverse effects
  • Heptanoic Acids
  • Heptanoic Acids - administration & dosage
  • Heptanoic Acids - adverse effects
  • Humans
  • Hydroxymethylglutaryl
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects
  • Hypercholesterolemia
  • Hypercholesterolemia - blood
  • Hypercholesterolemia - drug therapy
  • Lipids
  • lipids (amino acids
  • Male
  • MEDICAL AND HEALTH SCIENCES
  • MEDICIN OCH HÄLSOVETENSKAP
  • metabolic diseases
  • Middle Aged
  • nutritional
  • peptides
  • proteins
  • Pyrimidines
  • Pyrimidines - administration & dosage
  • Pyrimidines - adverse effects
  • Pyrroles
  • Pyrroles - administration & dosage
  • Pyrroles - adverse effects
  • Risk
  • Risk Assessment
  • Risk Factors
  • Rosuvastatin Calcium
  • Statins
  • Sulfonamides
  • Sulfonamides - administration & dosage
  • Sulfonamides - adverse effects
ispartof: Cardiology, 2008, Vol.111 (4), p.219-28
description: Patients at high risk of cardiovascular disease frequently fail to reach recommended low-density lipoprotein cholesterol (LDL-C) goals, partly because statin doses are not titrated to optimal effect. The ECLIPSE study was designed to compare the efficacy and safety of force-titrated treatment with rosuvastatin (10-40 mg) with that of atorvastatin (10-80 mg) in high-risk patients with hypercholesterolemia. In this 24-week, open-label, randomized, multinational, parallel-group study, 1,036 patients were randomized to rosuvastatin (n = 522) or atorvastatin (n = 514). At all time points, a significantly greater percentage of patients on rosuvastatin treatment achieved the NCEP ATP III LDL-C goal of
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0008-6312
fulltext: fulltext
issn:
  • 0008-6312
  • 1421-9751
  • 1421-9751
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.2324507
LOCALfalse
PrimoNMBib
record
control
sourceidproquest_swepu
recordidTN_cdi_swepub_primary_oai_gup_ub_gu_se_70461
sourceformatXML
sourcesystemPC
sourcerecordid1590587291
originalsourceidFETCH-LOGICAL-o330t-89c6b680fd3e3432a3bb4dbb5df2e442ea2dbbe1d6ac006ae2328f3f8ec0a08c3
addsrcrecordideNpVkV2rEzEQhhdRPPXohX9Agteu5qubXe-kVC0UFNTrMJtMTnNoN2s-LPtf_LEGWw94Ncw7T96ZzDTNS0bfMrYe3lFKGVdS8kfNiknO2kGt2eNmVfW-7QTjN82zlO5rKpXkT5sb1kshFR9Wze-tc96AWQhMluRwxAijP_q8kOBIDKn8gpQh--kvADnEB-F8wIm4EA222ecIGS2p8lyLOOVEzj4fyBz9CeJCDsuM0Rxqg5Qx1nDy8J5ETOVYURfDieQDku1mv_v6bUtSLnZ53jxxcEz44hpvmx8ft983n9v9l0-7zYd9G4Sgue0H041dT50VKKTgIMZR2nFcW8exbgWB1wyZ7cBQ2gFywXsnXI-GAu2NuG3eXHzTGecy6uvMOoDXd2XWVborOqFWVHas4rsLHmacwEf874GdMOu5VBWKlkp1daZ1byUTnTXGid4qGMAp2g12rF6vL15zDD9L3Y2-DyVO9be6XlQJzoSq0KsrVMYT2od2_84o_gAXoqLQ
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid274732137
display
typearticle
titleEfficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study
sourceAlma/SFX Local Collection
creatorFaergeman, Ole ; Hill, Laurie ; Windler, Eberhard ; Wiklund, Olov ; Asmar, Roland ; Duffield, Emma ; Sosef, Froukje
creatorcontribFaergeman, Ole ; Hill, Laurie ; Windler, Eberhard ; Wiklund, Olov ; Asmar, Roland ; Duffield, Emma ; Sosef, Froukje ; ECLIPSE Study Investigators ; Wallenberg Laboratory ; Institute of Medicine, Department of Molecular and Clinical Medicine ; Göteborgs universitet ; Gothenburg University ; Sahlgrenska Academy ; Sahlgrenska akademin ; Wallenberglaboratoriet ; Institutionen för medicin, avdelningen för molekylär och klinisk medicin
descriptionPatients at high risk of cardiovascular disease frequently fail to reach recommended low-density lipoprotein cholesterol (LDL-C) goals, partly because statin doses are not titrated to optimal effect. The ECLIPSE study was designed to compare the efficacy and safety of force-titrated treatment with rosuvastatin (10-40 mg) with that of atorvastatin (10-80 mg) in high-risk patients with hypercholesterolemia. In this 24-week, open-label, randomized, multinational, parallel-group study, 1,036 patients were randomized to rosuvastatin (n = 522) or atorvastatin (n = 514). At all time points, a significantly greater percentage of patients on rosuvastatin treatment achieved the NCEP ATP III LDL-C goal of <100 mg/dl (2.5 mmol/l), the 2003 European LDL-C target of <2.5 or 3.0 mmol/l (100 or 115 mg/dl) and the LDL-C goal of <70 mg/dl (1.8 mmol/l), a goal suggested for very high-risk patients (p < 0.001 for all). Rosuvastatin also achieved significantly greater improvements in components of the atherogenic lipid profile versus atorvastatin. Both treatments were well tolerated. Rosuvastatin titrated across its recommended dose range provides a more favorable effect on lipoprotein variables than atorvastatin, enabling more high-risk patients to achieve recommended LDL-C goals.
identifier
0ISSN: 0008-6312
1ISSN: 1421-9751
2EISSN: 1421-9751
3DOI: 10.1159/000127442
4PMID: 18434729
languageeng
publisherSwitzerland: S. Karger AG
subject
ispartofCardiology, 2008, Vol.111 (4), p.219-28
rights
0Copyright 2008 S. Karger AG, Basel.
1Copyright (c) 2008 S. Karger AG, Basel
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18434729$$D View this record in MEDLINE/PubMed
1$$Uhttps://gup.ub.gu.se/publication/70461$$DView record from Swedish Publication Index
search
creatorcontrib
0Faergeman, Ole
1Hill, Laurie
2Windler, Eberhard
3Wiklund, Olov
4Asmar, Roland
5Duffield, Emma
6Sosef, Froukje
7ECLIPSE Study Investigators
8Wallenberg Laboratory
9Institute of Medicine, Department of Molecular and Clinical Medicine
10Göteborgs universitet
11Gothenburg University
12Sahlgrenska Academy
13Sahlgrenska akademin
14Wallenberglaboratoriet
15Institutionen för medicin, avdelningen för molekylär och klinisk medicin
title
0Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study
1Cardiology
addtitleCardiology
descriptionPatients at high risk of cardiovascular disease frequently fail to reach recommended low-density lipoprotein cholesterol (LDL-C) goals, partly because statin doses are not titrated to optimal effect. The ECLIPSE study was designed to compare the efficacy and safety of force-titrated treatment with rosuvastatin (10-40 mg) with that of atorvastatin (10-80 mg) in high-risk patients with hypercholesterolemia. In this 24-week, open-label, randomized, multinational, parallel-group study, 1,036 patients were randomized to rosuvastatin (n = 522) or atorvastatin (n = 514). At all time points, a significantly greater percentage of patients on rosuvastatin treatment achieved the NCEP ATP III LDL-C goal of <100 mg/dl (2.5 mmol/l), the 2003 European LDL-C target of <2.5 or 3.0 mmol/l (100 or 115 mg/dl) and the LDL-C goal of <70 mg/dl (1.8 mmol/l), a goal suggested for very high-risk patients (p < 0.001 for all). Rosuvastatin also achieved significantly greater improvements in components of the atherogenic lipid profile versus atorvastatin. Both treatments were well tolerated. Rosuvastatin titrated across its recommended dose range provides a more favorable effect on lipoprotein variables than atorvastatin, enabling more high-risk patients to achieve recommended LDL-C goals.
subject
0Aged
1Atorvastatin Calcium
2Canada
3Cardiovascular disease
4Cholesterol
5Cholesterol, LDL - blood
6CoA Reductase Inhibitors
7Coronary Disease
8Coronary Disease - prevention & control
9Drug dosages
10Drug therapy
11European Union
12Female
13Fluorobenzenes
14Fluorobenzenes - administration & dosage
15Fluorobenzenes - adverse effects
16Heptanoic Acids
17Heptanoic Acids - administration & dosage
18Heptanoic Acids - adverse effects
19Humans
20Hydroxymethylglutaryl
21Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage
22Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects
23Hypercholesterolemia
24Hypercholesterolemia - blood
25Hypercholesterolemia - drug therapy
26Lipids
27lipids (amino acids
28Male
29MEDICAL AND HEALTH SCIENCES
30MEDICIN OCH HÄLSOVETENSKAP
31metabolic diseases
32Middle Aged
33nutritional
34peptides
35proteins
36Pyrimidines
37Pyrimidines - administration & dosage
38Pyrimidines - adverse effects
39Pyrroles
40Pyrroles - administration & dosage
41Pyrroles - adverse effects
42Risk
43Risk Assessment
44Risk Factors
45Rosuvastatin Calcium
46Statins
47Sulfonamides
48Sulfonamides - administration & dosage
49Sulfonamides - adverse effects
issn
00008-6312
11421-9751
21421-9751
fulltexttrue
rsrctypearticle
creationdate2008
recordtypearticle
recordideNpVkV2rEzEQhhdRPPXohX9Agteu5qubXe-kVC0UFNTrMJtMTnNoN2s-LPtf_LEGWw94Ncw7T96ZzDTNS0bfMrYe3lFKGVdS8kfNiknO2kGt2eNmVfW-7QTjN82zlO5rKpXkT5sb1kshFR9Wze-tc96AWQhMluRwxAijP_q8kOBIDKn8gpQh--kvADnEB-F8wIm4EA222ecIGS2p8lyLOOVEzj4fyBz9CeJCDsuM0Rxqg5Qx1nDy8J5ETOVYURfDieQDku1mv_v6bUtSLnZ53jxxcEz44hpvmx8ft983n9v9l0-7zYd9G4Sgue0H041dT50VKKTgIMZR2nFcW8exbgWB1wyZ7cBQ2gFywXsnXI-GAu2NuG3eXHzTGecy6uvMOoDXd2XWVborOqFWVHas4rsLHmacwEf874GdMOu5VBWKlkp1daZ1byUTnTXGid4qGMAp2g12rF6vL15zDD9L3Y2-DyVO9be6XlQJzoSq0KsrVMYT2od2_84o_gAXoqLQ
startdate2008
enddate2008
creator
0Faergeman, Ole
1Hill, Laurie
2Windler, Eberhard
3Wiklund, Olov
4Asmar, Roland
5Duffield, Emma
6Sosef, Froukje
generalS. Karger AG
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
63V.
77QO
87X7
97XB
1088E
118AO
128FD
138FI
148FJ
158FK
168G5
17ABUWG
18AZQEC
19BENPR
20DWQXO
21FR3
22FYUFA
23GHDGH
24GNUQQ
25GUQSH
26K9.
27M0S
28M1P
29M2O
30MBDVC
31P64
32PADUT
33PQEST
34PQQKQ
35PQUKI
36PRINS
37Q9U
38CLFQK
39ADTPV
40AOWAS
sort
creationdate2008
titleEfficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study
authorFaergeman, Ole ; Hill, Laurie ; Windler, Eberhard ; Wiklund, Olov ; Asmar, Roland ; Duffield, Emma ; Sosef, Froukje
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-o330t-89c6b680fd3e3432a3bb4dbb5df2e442ea2dbbe1d6ac006ae2328f3f8ec0a08c3
rsrctypearticles
prefilterarticles
languageeng
creationdate2008
topic
0Aged
1Atorvastatin Calcium
2Canada
3Cardiovascular disease
4Cholesterol
5Cholesterol, LDL - blood
6CoA Reductase Inhibitors
7Coronary Disease
8Coronary Disease - prevention & control
9Drug dosages
10Drug therapy
11European Union
12Female
13Fluorobenzenes
14Fluorobenzenes - administration & dosage
15Fluorobenzenes - adverse effects
16Heptanoic Acids
17Heptanoic Acids - administration & dosage
18Heptanoic Acids - adverse effects
19Humans
20Hydroxymethylglutaryl
21Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage
22Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects
23Hypercholesterolemia
24Hypercholesterolemia - blood
25Hypercholesterolemia - drug therapy
26Lipids
27lipids (amino acids
28Male
29MEDICAL AND HEALTH SCIENCES
30MEDICIN OCH HÄLSOVETENSKAP
31metabolic diseases
32Middle Aged
33nutritional
34peptides
35proteins
36Pyrimidines
37Pyrimidines - administration & dosage
38Pyrimidines - adverse effects
39Pyrroles
40Pyrroles - administration & dosage
41Pyrroles - adverse effects
42Risk
43Risk Assessment
44Risk Factors
45Rosuvastatin Calcium
46Statins
47Sulfonamides
48Sulfonamides - administration & dosage
49Sulfonamides - adverse effects
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Faergeman, Ole
1Hill, Laurie
2Windler, Eberhard
3Wiklund, Olov
4Asmar, Roland
5Duffield, Emma
6Sosef, Froukje
7ECLIPSE Study Investigators
8Wallenberg Laboratory
9Institute of Medicine, Department of Molecular and Clinical Medicine
10Göteborgs universitet
11Gothenburg University
12Sahlgrenska Academy
13Sahlgrenska akademin
14Wallenberglaboratoriet
15Institutionen för medicin, avdelningen för molekylär och klinisk medicin
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6ProQuest Central (Corporate)
7Biotechnology Research Abstracts
8Health & Medical Collection
9ProQuest Central (purchase pre-March 2016)
10Medical Database (Alumni Edition)
11ProQuest Pharma Collection
12Technology Research Database
13Hospital Premium Collection
14Hospital Premium Collection (Alumni Edition)
15ProQuest Central (Alumni) (purchase pre-March 2016)
16Research Library (Alumni Edition)
17ProQuest Central (Alumni Edition)
18ProQuest Central Essentials
19ProQuest Central
20ProQuest Central Korea
21Engineering Research Database
22Health Research Premium Collection
23Health Research Premium Collection (Alumni)
24ProQuest Central Student
25Research Library Prep
26ProQuest Health & Medical Complete (Alumni)
27Health & Medical Collection (Alumni Edition)
28Medical Database
29Research Library
30Research Library (Corporate)
31Biotechnology and BioEngineering Abstracts
32Research Library China
33ProQuest One Academic Eastern Edition
34ProQuest One Academic
35ProQuest One Academic UKI Edition
36ProQuest Central China
37ProQuest Central Basic
38OpenAIRE
39SwePub
40SwePub Articles
jtitleCardiology
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Faergeman, Ole
1Hill, Laurie
2Windler, Eberhard
3Wiklund, Olov
4Asmar, Roland
5Duffield, Emma
6Sosef, Froukje
aucorp
0ECLIPSE Study Investigators
1Wallenberg Laboratory
2Institute of Medicine, Department of Molecular and Clinical Medicine
3Göteborgs universitet
4Gothenburg University
5Sahlgrenska Academy
6Sahlgrenska akademin
7Wallenberglaboratoriet
8Institutionen för medicin, avdelningen för molekylär och klinisk medicin
formatjournal
genrearticle
ristypeJOUR
atitleEfficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study
jtitleCardiology
addtitleCardiology
date2008
risdate2008
volume111
issue4
spage219
epage28
pages219-28
issn
00008-6312
11421-9751
eissn1421-9751
abstractPatients at high risk of cardiovascular disease frequently fail to reach recommended low-density lipoprotein cholesterol (LDL-C) goals, partly because statin doses are not titrated to optimal effect. The ECLIPSE study was designed to compare the efficacy and safety of force-titrated treatment with rosuvastatin (10-40 mg) with that of atorvastatin (10-80 mg) in high-risk patients with hypercholesterolemia. In this 24-week, open-label, randomized, multinational, parallel-group study, 1,036 patients were randomized to rosuvastatin (n = 522) or atorvastatin (n = 514). At all time points, a significantly greater percentage of patients on rosuvastatin treatment achieved the NCEP ATP III LDL-C goal of <100 mg/dl (2.5 mmol/l), the 2003 European LDL-C target of <2.5 or 3.0 mmol/l (100 or 115 mg/dl) and the LDL-C goal of <70 mg/dl (1.8 mmol/l), a goal suggested for very high-risk patients (p < 0.001 for all). Rosuvastatin also achieved significantly greater improvements in components of the atherogenic lipid profile versus atorvastatin. Both treatments were well tolerated. Rosuvastatin titrated across its recommended dose range provides a more favorable effect on lipoprotein variables than atorvastatin, enabling more high-risk patients to achieve recommended LDL-C goals.
copSwitzerland
pubS. Karger AG
pmid18434729
doi10.1159/000127442